share_log

Panbela Therapeutics | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Panbela Therapeutics | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Panbela Therapeutics | 25-NSE:由交易所申报的注销已到期、已赎回、已兑付证券的通知
美股sec公告 ·  04/25 09:15
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc., listed on the Nasdaq Stock Market, is set to be removed from listing effective May 6, 2024. The decision comes after a series of evaluations by Nasdaq Staff, which concluded that the company no longer meets certain listing requirements, specifically those under Listing Rules 5550(a)(2) and 5550(b)(1). Panbela Therapeutics was initially notified of the potential delisting on November 28, 2023, and subsequently requested a hearing on December 5, 2023. Despite receiving an additional delisting determination on January 22, 2024, for failing to meet the requirements of Listing Rule 5550(a)(4), the company's appeal to remain listed was denied by the Panel on March 5, 2024. Following a suspension of its securities on March 7, 2024, the company's request for reconsideration was also denied on March 15, 2024. With no further appeals made to the Nasdaq Listing and Hearing Review Council, the Staff's decision to delist became final on April 19, 2024.
Panbela Therapeutics, Inc., listed on the Nasdaq Stock Market, is set to be removed from listing effective May 6, 2024. The decision comes after a series of evaluations by Nasdaq Staff, which concluded that the company no longer meets certain listing requirements, specifically those under Listing Rules 5550(a)(2) and 5550(b)(1). Panbela Therapeutics was initially notified of the potential delisting on November 28, 2023, and subsequently requested a hearing on December 5, 2023. Despite receiving an additional delisting determination on January 22, 2024, for failing to meet the requirements of Listing Rule 5550(a)(4), the company's appeal to remain listed was denied by the Panel on March 5, 2024. Following a suspension of its securities on March 7, 2024, the company's request for reconsideration was also denied on March 15, 2024. With no further appeals made to the Nasdaq Listing and Hearing Review Council, the Staff's decision to delist became final on April 19, 2024.
在纳斯达克股票市场上市的Panbela Therapeutics, Inc. 定于2024年5月6日起停止上市。该决定是在纳斯达克工作人员进行了一系列评估之后做出的,评估得出的结论是,该公司不再符合某些上市要求,特别是《上市规则》5550(a)(2)和5550(b)(1)的要求。Panbela Therapeutics最初于2023年11月28日收到可能的退市通知,随后要求在2023年12月5日举行听证会。尽管该公司因未能符合《上市规则》第5550 (a) (4) 条的要求而于2024年1月22日收到了额外的除牌决定,但该小组仍于2024年3月5日驳回了该公司继续上市的上诉。继2024年3月7日暂停证券后,该公司的重审请求也于2024年3月15日被拒绝。由于没有向纳斯达克上市和听证会审查委员会提出进一步上诉,工作人员的退市决定于2024年4月19日成为最终决定。
在纳斯达克股票市场上市的Panbela Therapeutics, Inc. 定于2024年5月6日起停止上市。该决定是在纳斯达克工作人员进行了一系列评估之后做出的,评估得出的结论是,该公司不再符合某些上市要求,特别是《上市规则》5550(a)(2)和5550(b)(1)的要求。Panbela Therapeutics最初于2023年11月28日收到可能的退市通知,随后要求在2023年12月5日举行听证会。尽管该公司因未能符合《上市规则》第5550 (a) (4) 条的要求而于2024年1月22日收到了额外的除牌决定,但该小组仍于2024年3月5日驳回了该公司继续上市的上诉。继2024年3月7日暂停证券后,该公司的重审请求也于2024年3月15日被拒绝。由于没有向纳斯达克上市和听证会审查委员会提出进一步上诉,工作人员的退市决定于2024年4月19日成为最终决定。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息